3D Medicines Inc. (HKG:1244)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.150
-0.170 (-5.12%)
May 7, 2026, 4:08 PM HKT
Market Cap772.96M -8.3%
Revenue (ttm)396.26M -20.1%
Net Income-197.56M
EPS-0.80
Shares Out245.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume141,500
Average Volume84,150
Open3.320
Previous Close3.320
Day's Range3.140 - 3.320
52-Week Range2.830 - 10.020
Beta0.22
RSI28.77
Earnings DateAug 28, 2026

About 3D Medicines

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in P... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 162
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1244
Full Company Profile

Financial Performance

In 2025, 3D Medicines's revenue was 356.09 million, a decrease of -20.10% compared to the previous year's 445.65 million. Losses were -177.53 million, -2.81% less than in 2024.

Financial numbers in CNY Financial Statements